Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting

作者: Nicolò Bizzarri , Antonio Gonzalez Martin , Jan Persson , Joanna Kacperczyk-Bartnik , Zoia Razumova

DOI: 10.1136/IJGC-2021-002577

关键词:

摘要: This is a report from the European Society of Gynaecological Oncology State-of-the-Art Virtual Meeting held December 14-16, 2020. The unique 3-day conference offered comprehensive state-of-the-art summaries on major advances in treatment different types gynecological cancers. Sessions opened with case presentation followed by keynote lecture and interactive debates opinion leaders field. speakers also presented scientific reviews clinical trial landscape collaboration Network Gynecological Oncological Trial (ENGOT) groups. In addition, new ESGO-ESRTO-ESP endometrial cancer guidelines were officially public. paper describes key information latest studies that for first time at conference.

参考文章(99)
Casper Tax, Maroeska M. Rovers, Corine de Graaf, Petra L.M. Zusterzeel, Ruud L.M. Bekkers, The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review Gynecologic Oncology. ,vol. 139, pp. 559- 567 ,(2015) , 10.1016/J.YGYNO.2015.09.076
Lobna Ouldamer, Henri Marret, Olivier Acker, Isabelle Barillot, Gilles Body, Unusual localizations of sentinel lymph nodes in early stage cervical cancer: a review. Surgical Oncology-oxford. ,vol. 21, ,(2012) , 10.1016/J.SURONC.2012.04.003
Ignace Vergote, Eric Pujade-Lauraine, Sandro Pignata, Gunnar B. Kristensen, Jonathan Ledermann, Antonio Casado, Jalid Sehouli, Mansoor Mirza, Roldano Fossati, Christian Marth, Carine Creutzberg, Jose Del Campo, Nadeem Siddiqui, Paula Calvert, Aris Bamias, Gokhan Tulunay, Ate G.J. van der Zee, Andreas du Bois, European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies International Journal of Gynecological Cancer. ,vol. 20, pp. 476- 478 ,(2010) , 10.1111/IGC.0B013E3181D3CAA8
Robert E. Bristow, Rafael S. Tomacruz, Deborah K. Armstrong, Edward L. Trimble, F. J. Montz, Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis Journal of Clinical Oncology. ,vol. 20, pp. 1248- 1259 ,(2002) , 10.1200/JCO.2002.20.5.1248
Marcos Ballester, Gil Dubernard, Fabrice Lécuru, Denis Heitz, Patrice Mathevet, Henri Marret, Denis Querleu, François Golfier, Eric Leblanc, Roman Rouzier, Emile Daraï, Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO) Lancet Oncology. ,vol. 12, pp. 469- 476 ,(2011) , 10.1016/S1470-2045(11)70070-5
Fabrice Lécuru, Patrice Mathevet, Denis Querleu, Eric Leblanc, Philipe Morice, Emile Daraï, Henri Marret, Laurent Magaud, Florence Gillaizeau, Gilles Chatellier, Daniel Dargent, Bilateral Negative Sentinel Nodes Accurately Predict Absence of Lymph Node Metastasis in Early Cervical Cancer: Results of the SENTICOL Study Journal of Clinical Oncology. ,vol. 29, pp. 1686- 1691 ,(2011) , 10.1200/JCO.2010.32.0432
TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, G Kristensen, MS Carey, P Beale, A Cervantes, C Kurzeder, A du Bois, J Sehouli, R Kimmig, A Stähle, F Collinson, S Essapen, C Gourley, A Lortholary, F Selle, MR Mirza, A Leminen, M Plante, D Stark, W Qian, AM Parmar, MK: Oza, ICON7 Investigators, None, A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine. ,vol. 365, pp. 2484- 2496 ,(2011) , 10.1056/NEJMOA1103799
Martin R. Stockler, Felix Hilpert, Michael Friedlander, Madeleine T. King, Lari Wenzel, Chee Khoon Lee, Florence Joly, Nikolaus de Gregorio, José Angel Arranz, Mansoor Raza Mirza, Roberto Sorio, Ulrich Freudensprung, Vesna Sneller, Gill Hales, Eric Pujade-Lauraine, Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer Journal of Clinical Oncology. ,vol. 32, pp. 1309- 1316 ,(2014) , 10.1200/JCO.2013.51.4240